Technical Analysis for NEVPF - Neurovive Pharm Ab Ord

Grade Last Price % Change Price Change
grade D 0.1545 2.66% 0.0040
NEVPF closed up 2.66 percent on Friday, January 24, 2020, on 1 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Down
Historical NEVPF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 2.66%
Wide Bands Range Expansion 2.66%
Gapped Up Strength 2.66%
MACD Bearish Centerline Cross Bearish 18.85%
MACD Bearish Signal Line Cross Bearish 18.85%
Volume Surge Other 18.85%
Narrow Range Bar Range Contraction 18.85%
Older signals for NEVPF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in Phase II clinical study for the treatment of traumatic brain injuries; and ToxPhos for the mitochondrial toxicity test. The company is also developing NVP015 for mitochondrial genetic disorders; NVP025 mitochondrial myopathies program; NV556 for the treatment of mitochondrial myopathy; NVP022 for targeting mitochondrial metabolic pathways in non-alcoholic steatohepatitis (NASH) and complementing NV556 in the treatment of NASH; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea, as well as agreements with Fresenius Kabi. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in mitochondrial medicine field. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Medical Specialties Organ Systems Sanofi Hepatocellular Carcinoma Steatohepatitis Sihuan Pharmaceutical Traumatic Brain Injuries

Is NEVPF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.47
52 Week Low 0.097
Average Volume 9,894
200-Day Moving Average 0.1692
50-Day Moving Average 0.1550
20-Day Moving Average 0.1557
10-Day Moving Average 0.1583
Average True Range 0.0168
ADX 16.39
+DI 35.5319
-DI 39.8298
Chandelier Exit (Long, 3 ATRs ) 0.1346
Chandelier Exit (Short, 3 ATRs ) 0.1804
Upper Bollinger Band 0.1814
Lower Bollinger Band 0.1300
Percent B (%b) 0.48
BandWidth 33.0122
MACD Line -0.0008
MACD Signal Line 0.0004
MACD Histogram -0.0012
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1545
Resistance 3 (R3) 0.1545 0.1545 0.1545
Resistance 2 (R2) 0.1545 0.1545 0.1545 0.1545
Resistance 1 (R1) 0.1545 0.1545 0.1545 0.1545 0.1545
Pivot Point 0.1545 0.1545 0.1545 0.1545 0.1545
Support 1 (S1) 0.1545 0.1545 0.1545 0.1545 0.1545
Support 2 (S2) 0.1545 0.1545 0.1545 0.1545
Support 3 (S3) 0.1545 0.1545 0.1545
Support 4 (S4) 0.1545